Live Earnings Conference Call: BioCryst Pharmaceuticals will host a live Q2 2025 earnings call on August 4, 2025 at 8:30AM ET. NASDAQ:BCRX BioCryst Pharmaceuticals Q2 2025 Earnings Report $7.95 -0.19 (-2.33%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.09 +0.14 (+1.70%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Live Call not available Upcoming EventEarnings Conference CallBioCryst Pharmaceuticals Q2 202500:00 / 00:00Live Transcript Follow Audio BioCryst Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.02Beat/MissN/AOne Year Ago EPSN/ABioCryst Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$149.59 millionBeat/MissN/AYoY Revenue GrowthN/ABioCryst Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/4/2025TimeBefore Market OpensConference Call DateMonday, August 4, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile BioCryst Pharmaceuticals Earnings HeadlinesBioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on MondayAugust 2 at 2:52 AM | americanbankingnews.comBioCryst Pharmaceuticals Q2 2025 Earnings PreviewAugust 1 at 12:41 PM | seekingalpha.comTrump Did What!?Last May, President Trump signed four executive orders that could spark the biggest energy disruption in decades. This move opens the door for a next-gen power source with the potential to upend oil and gas, slash emissions, and accelerate artificial intelligence breakthroughs. While stocks tied to this trend have already soared, one overlooked corner of the industry could deliver even bigger gains—and it’s still flying under the radar. | Stansberry Research (Ad)BioCryst Pharmaceuticals Announces CEO Transition | BCRX stock newsJuly 31, 2025 | gurufocus.comBioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in DecemberJuly 31, 2025 | globenewswire.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to "Strong-Buy" at Wall Street ZenJuly 28, 2025 | americanbankingnews.comSee More BioCryst Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioCryst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your email. Email Address About BioCryst PharmaceuticalsBioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.View BioCryst Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? Upcoming Earnings Advanced Micro Devices (8/5/2025)Marriott International (8/5/2025)Amgen (8/5/2025)Itau Unibanco (8/5/2025)Pfizer (8/5/2025)Coupang (8/5/2025)BP (8/5/2025)Mplx (8/5/2025)Aflac (8/5/2025)Arista Networks (8/5/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
